Manager TitleAgeSince
President 63 27/05/2010
Director TitleAgeSince
Director/Board Member 63 26/03/2010
Director/Board Member 85 01/06/2011
Director/Board Member 79 09/05/2013
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.40% - - 0
-0.62%-1.87%+46.31%+56.99% 6.38TCr
+0.35%+3.20%+14.92%+84.55% 5.64TCr
+0.53%+1.96%+15.37%+106.81% 5.46TCr
-2.81%-4.31%+23.50%+50.90% 4.41TCr
-0.33%-1.93%+20.15%+98.45% 4.21TCr
+0.55%+2.31%+224.97%+942.56% 4.1TCr
+3.27%+47.96%+112.67%+96.48% 3.49TCr
+1.22%-1.44%+14.89%+47.15% 3.28TCr
+0.89%+20.55%-42.03%+373.03% 2.47TCr
Average +0.31%+7.54%+47.86%+206.32% 4.38TCr
Weighted average by Cap. +0.18%+5.44%+48.50%+186.13%
Logo TESARO Inc
TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform. Rolapitant is a potent and long-acting neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Niraparib is an orally active and potent poly (adenosine diphosphate (ADP)-ribose) polymerase inhibitor. It has various ongoing clinical trials evaluating niraparib for the treatment of ovarian or breast cancers. It has initiated a Phase I, dose escalation study for its first immuno-oncology antibody, TSR-042, which targets Programmed cell death protein 1. It has commenced pre-clinical research for its antibody candidate targeting Lymphocyte-activation gene-3 andTSR-033. It has commenced a Phase I clinical trial of TSR-042.
Employees
-